High-Dose Convalescent Plasma for Treatment of Severe COVID-19

• DOI: 10.3201/eid2803.212299
• Publication Date: 2022-01-31T20:17:38Z
• Authors: Gil C. De Santis; Luciana Correa Ol...; Pedro M.M. Garibaldi; Carlos E.L. Almado; Julio Croda; Ghislaine G.A. Ar...; Érika A.F. Oliveira; Adriana C. Tonacio; Dante M. Langhi; José O. Bordin; Renato N. Gilio; Leonardo C. Palma; Elaine V. Santos; Simone K. Haddad; Benedito P.A. Prado; Marjorie Cornejo ...; Rogério Gomes; Carlos H. Miranda; Maria Auxiliadora...; Dimas T. Covas; Eurico Arruda; Benedito A.L. Fon...; Rodrigo T. Calado
• Keywords: Convalescent plasma; 2019-20 coronavirus outbreak

To assess whether high-dose coronavirus disease (COVID-19) convalescent plasma (CCP) transfusion may benefit patients with severe COVID-19, we conducted a multicenter randomized trial in Brazil. Patients COVID-19 who were within 10 days of initial symptom onset eligible. the CCP group received 3 daily doses (600 mL/d) addition to standard treatment; control treatment only. Primary outcomes death rates at 30 and 60 study randomization. Secondary ventilator-free hospital-free days. We enrolled 107 patients: 36 71 control. At day 30, 22% for 25% group; 60, 31% 35% Needs invasive mechanical ventilation durations hospital stay similar between groups. conclude that transfused provided no COVID-19.